ClinicalTrials.gg
RecruitingNCT03005132Updated Dec 29, 2016

Integrative Analysis of Human Glioblastoma Multiforme

An observational study in GBM, sponsored by Shanghai 10th People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-12-29.

Sponsored by Shanghai 10th People's Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
1,000
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 143 studies in Glioblastoma with a site in China — 74 open to participants now, 81 under way, 7 of them phase 3. Glioblastoma · China.

Planned enrollment
Largest of 15
1,000 · median 100
Started
2016
with 8 others
Observational
15 of 143
8 open now
Primary completion
2026-12
later than 37 of 80 live
Registered
21st of 143
by date

Among the 143 studies in Glioblastoma with a site in China, this one has the largest planned enrollment of the 15 observational ones that give a count, is one of 9 that started in 2016, is one of 15 observational ones, reaches primary completion later than 37 of the 80 other live ones, and was the 21st registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

74 of the 143 studies in Glioblastoma with a site in China are open now. Recruiting first, the newest first:

69 more — sign in →

All 74 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 143 studies in Glioblastoma with a site in China, or all of them as a file.
02

Study summary

Integrative analysis of GBM

Read the detailed description

The investigators will analyzed proteomes of paired normal brain tissues and GBM, sequenced transcriptomes, perform whole exome sequencing, and single nucleotide polymorphism (SNP) array profiling for triplets, each comprising normal brain tissue, primary GBM carcinoma, and its synchronous matched metastasis, as well as analyzed genomics of GBM characterized previously by The Cancer Genome Atlas (TCGA) to conduct integrated proteogenomic analyses.

03

Conditions studied

  • GBM

Browse trials for

Keywords

  • GBM; Integrative Analysis; WES
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with GBM

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≤ 75 years with proven GBM
  • No severe major organ dysfunction
  • World Health Organization (WHO) performance status of 0 or 1
  • No prior cancer chemotherapy

Exclusion criteria

Exclusion Criteria:

  • Age ≥ 76
  • Severe major organ dysfunction
  • of >1
  • Prior cancer chemotherapy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Normal brain tissue

    Normal brain tissue from GBM patients

    Other: Normal brain tissue

  • GBM tissues

    GBM tissues from GBM patients

    Other: Normal brain tissue

  • Metastasis tissues

    Metastasis tissues from GBM patients

    Other: Normal brain tissue

Interventions

  • OtherNormal brain tissue

    The investigators will extract total protein, DNA and RNA from the samples.

06

What researchers measure

Primary outcomes

  1. 5 years overall survival

    Time frame: 5 years

Secondary outcomes

  1. 5 years disease-free survival

    Time frame: 5 years

  2. 10 years overall survival

    Time frame: 10 years

  3. 10 years disease-free survival

    Time frame: 10 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4. PubMed 25651787 ↗

Individual participant data

Plan to share: Yes — The investigators are willing to share data.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2016, a primary completion of Dec 2026 and a completion of Dec 2026. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2016
First posted
Dec 29, 2016
Start
Jan 2016
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Dec 29, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03005132
Collaborators
Jilin University, Ganzhou City People's Hospital
Responsible party
Da Fu (Principal Investigator, Shanghai 10th People's Hospital) — Principal investigator
First posted
Dec 29, 2016
Start date
Jan 2016
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Dec 29, 2016

Study contacts

Da Fu, PhD
Contact
fu800da900@126.com
00-86-21-66301604
Yushui Ma, BS
Contact
mayushui2015@126.com
00-86-21-66301604
Da Fu, PhD
principal investigator · Shanghai 10th People's Hospital
Xiaoming Zhong, MD
study director · Ganzhou City People's Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion